Effect of insulin on farnesyltransferase. Specificity of insulin action and potentiation of nuclear effects of insulin-like growth factor-1, epidermal growth factor, and platelet-derived growth factor.
We have previously demonstrated that insulin activates farnesyltransferase (FTase) and augments the amounts of farnesylated p21 (Goalstone, M. L., and Draznin, B. (1996) J. Biol. Chem. 271, 27585-27589). We postulated that this aspect of insulin action might explain the "priming effect" of insulin on the cellular response to other growth factors. In the present study, we show the specificity of the effect of insulin on FTase. Insulin, but not insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), or platelet-derived growth factor (PDGF), stimulated the phosphorylation of the alpha-subunit of FTase and the amounts of farnesylated p21. Even though all four growth factors utilized the Ras pathway to stimulate DNA synthesis, only insulin used this pathway to influence FTase. Insulin failed to stimulate FTase in cells expressing the chimeric insulin/IGF-1 receptor and in cells derived from the insulin receptor knock-out animals. Insulin potentiated the effects of IGF-1, EGF, and PDGF on DNA synthesis in cells expressing the wild type insulin receptor, but this potentiation was inhibited in the presence of the FTase inhibitor, alpha-hydroxyfarnesylphosphonic acid. We conclude that the effect of insulin on FTase is specific, requires the presence of an intact insulin receptor, and serves as a conduit for the "priming" influence of insulin on the nuclear effects of other growth factors.
Goalstone
M L
ML
Research Service and the Department of Medicine, Denver Veterans Affairs Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA.
Leitner
J W
JW
Wall
K
K
Dolgonos
L
L
Rother
K I
KI
Accili
D
D
Draznin
B
B
D016475:3T3 Cells; D019883:Alkyl and Aryl Transferases / Q000378:metabolism*; D000818:Animals; D002455:Cell Division; D004247:DNA / Q000096:biosynthesis; D004815:Epidermal Growth Factor / Q000494:pharmacology* / Q000502:physiology; D051231:Farnesyltranstransferase; D007328:Insulin / Q000494:pharmacology* / Q000502:physiology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology* / Q000502:physiology; D007700:Kinetics; D051379:Mice; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology* / Q000502:physiology; D017368:Protein Prenylation; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism*; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis / Q000502:physiology*; D011972:Receptor, Insulin / Q000096:biosynthesis / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D014162:Transfection
D007328:Insulin; D010982:Platelet-Derived Growth Factor; D011993:Recombinant Fusion Proteins; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D004247:DNA; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; D016283:Proto-Oncogene Proteins p21(ras)